“Pharmacogenetics of Cancer”-Cancer Drug Resistance special issue  

作　　者：Enrico Mini Stefania Nobili 

机构地区：[1]Department of Health Sciences,Section of Clinical Pharmacology and Oncology,University of Florence,Florence 50139,Italy [2]Cancer Pharmacology Working Group of the Italian Society of Pharmacology,Milan 20129,Italy

出　　处：《Cancer Drug Resistance》2020年第2期225-231,共7页癌症耐药（英文）

摘　　要：Pharmacogenetics and pharmacogenomics have expanded rapidly over the past years and represent one of the bases of precision medicine.The application of pharmacogenetic and pharmacogenomic approaches and tools for the selection of medications and their dosage to improve patient care is nowadays substantially increased[1,2].Prescription drug information sheets in several therapeutic areas(psychiatric,cardiovascular,analgesic,antiviral,and anticancer drugs)provide current information on pharmacogenetic and pharmacogenomic biomarkers for over 200 medicines including mandatory or recommended biomarker testing prior to initiating therapy[3].

关 键 词：DOSAGE BASES initiating 

分 类 号：R73[医药卫生—肿瘤]